» Articles » PMID: 28402630

Benzoisoquinolinediones As Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains

Abstract

Bromodomains (BD) are readers of lysine acetylation marks present in numerous proteins associated with chromatin. Here we describe a dual inhibitor of the bromodomain and PHD finger (BRPF) family member BRPF2 and the TATA box binding protein-associated factors TAF1 and TAF1L. These proteins are found in large chromatin complexes and play important roles in transcription regulation. The substituted benzoisoquinolinedione series was identified by high-throughput screening, and subsequent structure-activity relationship optimization allowed generation of low nanomolar BRPF2 BD inhibitors with strong selectivity against BRPF1 and BRPF3 BDs. In addition, a strong inhibition of TAF1/TAF1L BD2 was measured for most derivatives. The best compound of the series was BAY-299, which is a very potent, dual inhibitor with an IC of 67 nM for BRPF2 BD, 8 nM for TAF1 BD2, and 106 nM for TAF1L BD2. Importantly, no activity was measured for BRD4 BDs. Furthermore, cellular activity was evidenced using a BRPF2- or TAF1-histone H3.3 or H4 interaction assay.

Citing Articles

Harnessing the TAF1 Acetyltransferase for Targeted Acetylation of the Tumor Suppressor p53.

Kabir M, Hu X, Martin T, Pokushalov D, Kim Y, Chen Y Adv Sci (Weinh). 2024; 12(7):e2413377.

PMID: 39716936 PMC: 11831463. DOI: 10.1002/advs.202413377.


Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran -Active KAT6AB Inhibitor.

Ter Laak A, Hillig R, Ferrara S, Korr D, Barak N, Lienau P J Med Chem. 2024; 67(21):19282-19303.

PMID: 39450890 PMC: 11571114. DOI: 10.1021/acs.jmedchem.4c01709.


The ORFIUS complex regulates ORC2 localization at replication origins.

Yang Z, Mogre S, He R, Berdan E, Ho Sui S, Hill S NAR Cancer. 2024; 6(1):zcae003.

PMID: 38288445 PMC: 10823580. DOI: 10.1093/narcan/zcae003.


Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening.

Kumar V, Lakshman P, Prasad T, Manjunath K, Bairy S, Vasu A Heliyon. 2024; 10(1):e23864.

PMID: 38226204 PMC: 10788520. DOI: 10.1016/j.heliyon.2023.e23864.


Bromodomain inhibitors and therapeutic applications.

Gajjela B, Zhou M Curr Opin Chem Biol. 2023; 75:102323.

PMID: 37207401 PMC: 10524616. DOI: 10.1016/j.cbpa.2023.102323.


References
1.
Vidler L, Brown N, Knapp S, Hoelder S . Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem. 2012; 55(17):7346-59. PMC: 3441041. DOI: 10.1021/jm300346w. View

2.
Bamborough P, Barnett H, Becher I, Bird M, Chung C, Craggs P . GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain. ACS Med Chem Lett. 2016; 7(6):552-7. PMC: 4904261. DOI: 10.1021/acsmedchemlett.6b00092. View

3.
Louder R, He Y, Lopez-Blanco J, Fang J, Chacon P, Nogales E . Structure of promoter-bound TFIID and model of human pre-initiation complex assembly. Nature. 2016; 531(7596):604-9. PMC: 4856295. DOI: 10.1038/nature17394. View

4.
Emsley P, Lohkamp B, Scott W, Cowtan K . Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 4):486-501. PMC: 2852313. DOI: 10.1107/S0907444910007493. View

5.
Filippakopoulos P, Knapp S . Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014; 13(5):337-56. DOI: 10.1038/nrd4286. View